Login to Your Account


Study could help company establish broad label

A phase III trial testing Astellas Pharma Inc.’s AML candidate, gilteritinib, as a maintenance therapy after hematopoietic stem cell transplant (HCT) has dosed its first patient. more »


Our Habitat for All Things Science
Nuclear factor controlling brown fat gene identified

A study reported Aug. 14, 2017 in Nature Cell Biology has identified a nuclear factor involved in brown fat metabolism that contributes to the pathophysiology of obesity in humans, which could lead to the development of new brown fat-targeted anti-obesity therapies.

The world's population is experiencing an epidemic of obesity and complications including diabetes and atherosclerosis. The World Health Organization estimates that global obesity more than doubled between 1980 and 2014, with almost 2 billion adults being overweight in 2015.

READ MORE »

Opinion


Partners in Focus